JP2023513015A5 - - Google Patents
Info
- Publication number
- JP2023513015A5 JP2023513015A5 JP2022546004A JP2022546004A JP2023513015A5 JP 2023513015 A5 JP2023513015 A5 JP 2023513015A5 JP 2022546004 A JP2022546004 A JP 2022546004A JP 2022546004 A JP2022546004 A JP 2022546004A JP 2023513015 A5 JP2023513015 A5 JP 2023513015A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- week
- kras
- administered
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062968615P | 2020-01-31 | 2020-01-31 | |
| US62/968,615 | 2020-01-31 | ||
| US202063115433P | 2020-11-18 | 2020-11-18 | |
| US63/115,433 | 2020-11-18 | ||
| PCT/US2021/015401 WO2021154929A1 (en) | 2020-01-31 | 2021-01-28 | Combination therapy for treating abnormal cell growth |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023513015A JP2023513015A (ja) | 2023-03-30 |
| JP2023513015A5 true JP2023513015A5 (enExample) | 2024-01-22 |
Family
ID=77079417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022546004A Pending JP2023513015A (ja) | 2020-01-31 | 2021-01-28 | 異常な細胞成長を処置するための併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230103007A1 (enExample) |
| EP (1) | EP4096671B1 (enExample) |
| JP (1) | JP2023513015A (enExample) |
| KR (1) | KR20230011908A (enExample) |
| CN (1) | CN115279376A (enExample) |
| AU (1) | AU2021213753A1 (enExample) |
| BR (1) | BR112022015161A2 (enExample) |
| CA (1) | CA3168648A1 (enExample) |
| IL (1) | IL295117A (enExample) |
| MX (1) | MX2022009347A (enExample) |
| WO (1) | WO2021154929A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| EP4062914A4 (en) | 2019-11-18 | 2024-01-17 | Inxmed (Nanjing) Co., Ltd. | USE OF AN FAK INHIBITOR IN THE PREPARATION OF A DRUG FOR THE TREATMENT OF TUMORS PRESENTING AN NRAS MUTATION |
| AU2021206684B2 (en) | 2020-01-10 | 2024-01-18 | Immuneering Corporation | MEK inhibitors and therapeutic uses thereof |
| EP4101453A4 (en) | 2020-02-05 | 2024-05-15 | Inxmed (Nanjing) Co., Ltd. | COMBINATION OF BI853520 WITH CHEMOTHERAPEUTIC DRUGS |
| ES3049298T3 (en) * | 2020-08-03 | 2025-12-16 | Inxmed Nanjing Co Ltd | Solid form of compound |
| WO2022165142A1 (en) * | 2021-01-29 | 2022-08-04 | Mirati Therapeutics, Inc. | Combination therapies |
| US12280055B2 (en) * | 2021-05-27 | 2025-04-22 | Mirati Therapeutics, Inc. | Combination therapies |
| TW202313044A (zh) * | 2021-08-16 | 2023-04-01 | 大陸商應世生物科技（南京）有限公司 | Ｉｎ１００１８與ｐｌｄ的聯用 |
| CN114133355B (zh) * | 2021-11-29 | 2023-09-15 | 郑州大学第一附属医院 | 一种2-苯基-1h-苯并咪唑类衍生物及其应用 |
| JP2024545147A (ja) * | 2021-12-10 | 2024-12-05 | ▲應▼世生物科技（南京）有限公司 | 腫瘍治療の医薬組合せ及び使用 |
| WO2023108110A2 (en) * | 2021-12-10 | 2023-06-15 | Verastem, Inc. | Combination therapy for treating abnormal cell growth |
| CA3252402A1 (en) * | 2022-02-28 | 2025-07-07 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | COMPOUND USED AS A FAK INHIBITOR AND ITS USE |
| JP7565132B2 (ja) * | 2022-04-20 | 2024-10-10 | 中外製薬株式会社 | がんの治療又は予防用医薬 |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| WO2023246869A1 (zh) * | 2022-06-24 | 2023-12-28 | 应世生物科技(南京)有限公司 | 治疗肿瘤的药物组合及用途 |
| CN119451679A (zh) * | 2022-08-24 | 2025-02-14 | 应世生物科技(南京)有限公司 | Fak抑制剂及微管抑制剂的药物组合及用途 |
| CN119947725A (zh) * | 2022-09-30 | 2025-05-06 | 应世生物科技(南京)有限公司 | Fak抑制剂及诱导免疫原性细胞死亡的物质的药物组合及用途 |
| JP2026503267A (ja) * | 2023-01-06 | 2026-01-28 | エラスカ，インク． | Ｒａｆ阻害剤およびｋｒａｓ ｇ１２ｃ阻害剤の併用療法 |
| CN115845065A (zh) * | 2023-01-09 | 2023-03-28 | 江苏省原子医学研究所 | Fn/fak通路抑制剂在制备提高甲状腺癌放射性碘治疗敏感性的药物中的用途 |
| US12254987B2 (en) * | 2023-03-23 | 2025-03-18 | Certis Oncology Solutions, Inc. | Artificial intelligence for identifying one or more predictive biomarkers |
| WO2024199466A1 (zh) * | 2023-03-31 | 2024-10-03 | 应世生物科技(南京)有限公司 | 提高大分子药物在肿瘤组织中的浓度的方法 |
| WO2025079712A1 (ja) * | 2023-10-12 | 2025-04-17 | 中外製薬株式会社 | ドライバー変異を有するがん患者における分子標的薬併用療法 |
| WO2025106901A1 (en) * | 2023-11-17 | 2025-05-22 | Quanta Therapeutics, Inc. | Combination cancer therapies with a kras modulator and an rtk-mapk pathway inhibitor |
| WO2025149017A1 (zh) * | 2024-01-11 | 2025-07-17 | 四川弘合生物科技有限公司 | 一种包含榄香烯和激酶抑制剂的药物 |
| WO2025157162A1 (zh) * | 2024-01-22 | 2025-07-31 | 应世生物科技(南京)有限公司 | Fak抑制剂与kras g12c抑制剂的联用 |
| WO2025261307A1 (zh) * | 2024-06-17 | 2025-12-26 | 首药控股(北京)股份有限公司 | 治疗肿瘤的药物组合及用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105163584B (zh) * | 2013-03-05 | 2019-06-04 | 田纳西大学研究基金会 | 用于治疗癌症的化合物 |
| WO2015120289A1 (en) * | 2014-02-07 | 2015-08-13 | Verastem, Inc. | Methods and compositions for treating abnormal cell growth |
| US10532056B2 (en) * | 2015-06-29 | 2020-01-14 | Verastem, Inc. | Therapeutic compositions, combinations, and methods of use |
| US11286469B2 (en) * | 2017-11-09 | 2022-03-29 | Wisconsin Alumni Research Foundation | Combination chemotherapy for the treatment of cancer |
| WO2020023851A1 (en) * | 2018-07-26 | 2020-01-30 | Yale University | Bifunctional substitued pyrimidines as modulators of fak proteolyse |
| JP7377679B2 (ja) * | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| BR112022010278A2 (pt) * | 2019-11-27 | 2022-10-04 | Turning Point Therapeutics Inc | Terapia combinada que envolve compostos macrocíclicos de diarila |
-
2021
- 2021-01-28 WO PCT/US2021/015401 patent/WO2021154929A1/en not_active Ceased
- 2021-01-28 CN CN202180012207.9A patent/CN115279376A/zh active Pending
- 2021-01-28 AU AU2021213753A patent/AU2021213753A1/en active Pending
- 2021-01-28 KR KR1020227030021A patent/KR20230011908A/ko active Pending
- 2021-01-28 US US17/795,402 patent/US20230103007A1/en active Pending
- 2021-01-28 MX MX2022009347A patent/MX2022009347A/es unknown
- 2021-01-28 JP JP2022546004A patent/JP2023513015A/ja active Pending
- 2021-01-28 CA CA3168648A patent/CA3168648A1/en active Pending
- 2021-01-28 EP EP21747362.8A patent/EP4096671B1/en active Active
- 2021-01-28 BR BR112022015161A patent/BR112022015161A2/pt unknown
- 2021-01-28 IL IL295117A patent/IL295117A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023513015A5 (enExample) | ||
| JP2023534009A5 (enExample) | ||
| EP4337191B1 (en) | Egfr inhibitor for the treatment of head and neck cancer | |
| JP2023523323A5 (enExample) | ||
| JP2022009090A5 (enExample) | ||
| JP2017505321A5 (enExample) | ||
| US20180256578A1 (en) | A Combination Therapy Comprising Varlitinib and an Anticancer Agent | |
| JP2024528039A5 (enExample) | ||
| JP2021520406A5 (enExample) | ||
| JP2024527109A5 (enExample) | ||
| JP2024502446A5 (enExample) | ||
| JP2023553533A5 (enExample) | ||
| Lee et al. | Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer | |
| JP2020536048A5 (enExample) | ||
| Solomon et al. | Safety, pharmacokinetics, and antitumor activity findings from a phase 1b, open-label, dose-escalation and expansion study investigating RAF dimer inhibitor lifirafenib in combination with MEK inhibitor mirdametinib in patients with advanced or refractory solid tumors | |
| Zhang et al. | Successful treatment of ovarian cancer with apatinib combined with chemotherapy: a case report | |
| CN119497618A (zh) | 药物组合产品以及组合疗法 | |
| Shin et al. | The efficacy of paclitaxel and cisplatin combination chemotherapy for the treatment of metastatic or recurrent gastric cancer: a multicenter phase II study | |
| CN111728974B (zh) | 西奥罗尼用于小细胞肺癌的治疗 | |
| JP2024506385A5 (enExample) | ||
| CN117959315B (zh) | 化合物pgg作为krasg12d抑制剂mrt1133的增效剂联合治疗胰腺癌的应用 | |
| JP2022542725A (ja) | 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用 | |
| CN117357534A (zh) | 包含维甲酸的药物组合物在制备治疗肝细胞癌伴腹腔转移的药物中的用途 | |
| CA3100422A1 (en) | Dosing regimens for treatment of solid tumors having one or more genetic alterations in fgfr1, fgfr2, and/or fgfr3 | |
| Li et al. | Conversion chemotherapy with capecitabine and oxaliplatin for colorectal cancer with potentially resectable liver metastases: A phase II, open-label, single-arm study |